

A Systematic Review of the Cost and Cost Effectiveness Multidrug-Resistant Tuberculosis

Pharmacoeconomics

30, 63-80

DOI: 10.2165/11595340-000000000-00000

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. European Respiratory Journal, 2011, 38, 516-528. | 6.7 | 718 |
| 2 | Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2012, 16, 955-960. | 1.2 | 30 |
| 3 | Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?. European Respiratory Journal, 2012, 40, 9-11. | 6.7 | 30 |
| 5 | Ensure a comprehensive approach when treating drug-resistant tuberculosis. Drugs and Therapy Perspectives, 2012, 28, 15-18. | 0.6 | 0 |
| 6 | Implementing the Global Plan to Stop TB, 2011â€“2015 â€“ Optimizing Allocations and the Global Fundâ€™s Contribution: A Scenario Projections Study. PLoS ONE, 2012, 7, e38816. | 2.5 | 17 |
| 7 | Decentralisation of multidrug-resistant-tuberculosis care and management. Lancet Infectious Diseases, The, 2013, 13, 644-646. | 9.1 | 12 |
| 8 | Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study. Lancet Infectious Diseases, The, 2013, 13, 777-784. | 9.1 | 27 |
| 9 | Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002â€“11, and requirements to meet 2015 targets. The Lancet Global Health, 2013, 1, e105-e115. | 6.3 | 39 |
| 10 | Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 299-307. | 1.2 | 119 |
| 11 | Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Tropical Medicine and International Health, 2013, 18, 109-116. | 2.3 | 40 |
| 12 | Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infectious Diseases, The, 2013, 13, 690-697. | 9.1 | 72 |
| 13 | Multidrug-Resistant Tuberculosis, Somalia, 2010â€“2011. Emerging Infectious Diseases, 2013, 19, 478-480. | 4.3 | 34 |
| 14 | Upperâ€“Room Ultraviolet Germicidal Irradiation (UVGI) for Air Disinfection: A Symposium in Print. Photochemistry and Photobiology, 2013, 89, 764-769. | 2.5 | 27 |
| 15 | A Systematic Review of the Effectiveness of Hospital- and Ambulatory-Based Management of Multidrug-Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2013, 89, 271-280. | 1.4 | 63 |
| 16 | Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB). Clinical Medicine Insights Therapeutics, 2013, 5, CMT.S11675. | 0.4 | 8 |
| 17 | Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. European Respiratory Journal, 2013, 42, 708-720. | 6.7 | 85 |
| 18 | Economic Evaluation of Diagnosis Tuberculosis in Hospital Setting. , 2013, , . | | 0 |
| 19 | Clinical Management of Drug-Resistant Tuberculosis in Resource Constrained Settings. Clinical Medicine Insights Therapeutics, 2013, 5, CMT.S6560. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 20 | What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?. PLoS ONE, 2013, 8, e54587. | 2.5 | 187 |
| 21 | Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes. PLoS ONE, 2013, 8, e70064. | 2.5 | 39 |
| 22 | Health Technology, Quality, Law, and Ethics. , 2014, , 771-819. | | 4 |
| 23 | Are We Doing Enough to Stem the Tide of Acquired MDR-TB in Countries with High TB Burden? Results of a Mixed Method Study in Chongqing, China. PLoS ONE, 2014, 9, e88330. | 2.5 | 27 |
| 24 | Diabetes Mellitus, Smoking Status, and Rate of Sputum Culture Conversion in Patients with Multidrug-Resistant Tuberculosis: A Cohort Study from the Country of Georgia. PLoS ONE, 2014, 9, e94890. | 2.5 | 38 |
| 25 | Drug-resistant tuberculosis: collaborative regional leadership required. Medical Journal of Australia, 2014, 200, 241-242. | 1.7 | 10 |
| 26 | Cost for Tuberculosis Care in Developed Countries: Which Data for an Economic Evaluation?. Journal of rheumatology Supplement, The, 2014, 91, 83-85. | 2.2 | 1 |
| 27 | Drug-Resistant Tuberculosis. , 2014, , 1-20. | | 0 |
| 28 | Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. European Respiratory Journal, 2014, 43, 1563-1566. | 6.7 | 36 |
| 29 | Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1019-1025. | 1.2 | 117 |
| 30 | Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. European Respiratory Journal, 2014, 44, 23-63. | 6.7 | 256 |
| 31 | Interpersonal psychotherapy versus treatment as usual for PTSD and depression among Sichuan earthquake survivors: a randomized clinical trial. Conflict and Health, 2014, 8, 14. | 2.7 | 26 |
| 32 | Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. European Respiratory Journal, 2014, 43, 1763-1775. | 6.7 | 423 |
| 33 | Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infectious Diseases, 2014, 14, 333. | 2.9 | 59 |
| 34 | “Home is where the patient is”: a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis. BMC Health Services Research, 2014, 14, 81. | 2.2 | 43 |
| 35 | Weight variation over time and its relevance among multidrug-resistant tuberculosis patients. International Journal of Infectious Diseases, 2014, 23, 20-24. | 3.3 | 19 |
| 36 | Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1443-1448. | 1.2 | 19 |
| 37 | Ambulatory tuberculosis treatment in post-Semashko health care systems needs supportive financing mechanisms. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1390-1395. | 1.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 38 | A case of M anila type M ycobacterium tuberculosis infection in J apan. Clinical Case Reports (discontinued), 2015, 3, 622-625. | 0.5 | 1 |
| 39 | Cost per patient of treatment for rifampicinâ€resistant tuberculosis in a communityâ€based programme in Khayelitsha, South Africa. Tropical Medicine and International Health, 2015, 20, 1337-1345. | 2.3 | 31 |
| 40 | The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study. BMC Infectious Diseases, 2015, 15, 473. | 2.9 | 4 |
| 41 | Cost-Effectiveness Analysis of Community Active Case Finding and Household Contact Investigation for Tuberculosis Case Detection in Urban Africa. PLoS ONE, 2015, 10, e0117009. | 2.5 | 47 |
| 42 | Loss from Treatment for Drug Resistant Tuberculosis: Risk Factors and Patient Outcomes in a Community-Based Program in Khayelitsha, South Africa. PLoS ONE, 2015, 10, e0118919. | 2.5 | 26 |
| 43 | A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children. International Journal of Tuberculosis and Lung Disease, 2015, 19, 55-60. | 1.2 | 12 |
| 44 | Cost effectiveness of treating multi-drug resistant tuberculosis by adding Delybaâ„¢ to background regimens in Germany. Respiratory Medicine, 2015, 109, 632-641. | 2.9 | 19 |
| 45 | Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. Pharmacoeconomics, 2015, 33, 939-955. | 3.3 | 131 |
| 46 | Use of quality checklists and need for disease-specific guidance in economic evaluations: a meta-review. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 675-685. | 1.4 | 4 |
| 47 | A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak. European Respiratory Journal, 2015, 46, 293-296. | 6.7 | 43 |
| 48 | Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. International Journal of Tuberculosis and Lung Disease, 2015, 19, 413-419. | 1.2 | 19 |
| 49 | Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China. Clinical Microbiology and Infection, 2015, 21, 1093.e9-1093.e18. | 6.0 | 12 |
| 50 | Anti-TB drug resistance in Tanga, Tanzania: A cross sectional facility-base prevalence among pulmonary TB patients. Asian Pacific Journal of Tropical Medicine, 2015, 8, 907-913. | 0.8 | 12 |
| 51 | Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012â€2014. Emerging Infectious Diseases, 2016, 22, 491-502. | 4.3 | 60 |
| 52 | New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Gastroenterology Insights, 2016, 8, 6569. | 1.2 | 53 |
| 53 | Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol. BMJ Open, 2016, 6, e014386. | 1.9 | 8 |
| 54 | More on Treatment Outcomes in Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2016, 375, 2609-2611. | 27.0 | 9 |
| 55 | Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature. Health Economics (United Kingdom), 2016, 25, 9-28. | 1.7 | 72 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 56 | Variation in policy and practice of adolescent tuberculosis management in the WHO European Region. <i>European Respiratory Journal</i> , 2016, 48, 943-946. | 6.7 | 8 |
| 57 | Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 901-915. | 4.4 | 62 |
| 58 | The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan. <i>BMC Infectious Diseases</i> , 2016, 16, 470. | 2.9 | 47 |
| 59 | Lobar Collapse Therapy Using Endobronchial Valves as a New Complementary Approach to Treat Cavities in Multidrug-Resistant Tuberculosis and Difficult-to-Treat Tuberculosis: A Case Series. <i>Respiration</i> , 2016, 92, 316-328. | 2.6 | 18 |
| 61 | Psychosocial wellbeing of patients with multidrug resistant tuberculosis voluntarily confined to long-term hospitalisation in Nigeria. <i>BMJ Global Health</i> , 2016, 1, e000006. | 4.7 | 11 |
| 62 | Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan. <i>Health Economics Review</i> , 2016, 6, 28. | 2.0 | 13 |
| 63 | Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. <i>Global Health Research and Policy</i> , 2016, 1, 10. | 3.6 | 14 |
| 64 | WHO strategies for the programmatic management of drug-resistant tuberculosis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 991-1002. | 2.5 | 34 |
| 65 | Rationing tests for drug-resistant tuberculosis – who are we prepared to miss?. <i>BMC Medicine</i> , 2016, 14, 30. | 5.5 | 7 |
| 66 | Characteristics and costs of multidrug-resistant tuberculosis in-patient care in the United States, 2005–2007. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 435-441. | 1.2 | 26 |
| 67 | Health technology assessment in low- and middle-income countries: a landscape assessment. <i>Journal of Pharmaceutical Health Services Research</i> , 2016, 7, 37-42. | 0.6 | 32 |
| 68 | Diagnostic usefulness of the GenoType MTBDRplus assay for detecting drug-resistant tuberculosis using AFB smear-negative specimens with positive TB-PCR result. <i>Infectious Diseases</i> , 2016, 48, 350-355. | 2.8 | 3 |
| 69 | Transmission and Institutional Infection Control of Tuberculosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a018192. | 6.2 | 62 |
| 70 | Drug-Resistant Tuberculosis. , 2017, , 263-286. | | 0 |
| 71 | The experience of scaling up a decentralized, ambulatory model of care for management of multidrug-resistant tuberculosis in two regions of Ethiopia. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2017, 7, 28-33. | 1.3 | 8 |
| 72 | The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 291-360. | 10.7 | 459 |
| 73 | Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. <i>BMC Health Services Research</i> , 2017, 17, 87. | 2.2 | 23 |
| 74 | Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1283105. | 1.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 75 | Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. <i>International Journal of Infectious Diseases</i> , 2017, 56, 185-189. | 3.3 | 14 |
| 76 | The long and winding road to inhaled TB therapy: not only the bug's fault. <i>Drug Development and Industrial Pharmacy</i> , 2017, 43, 347-363. | 2.0 | 15 |
| 77 | Community-based management of multiple drug resistant tuberculosis in a tertiary hospital in Tanzania: a best practice implementation project. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2017, 15, 3092-3101. | 1.7 | 2 |
| 78 | Multidrug-resistant tuberculosis and migration to Europe. <i>Clinical Microbiology and Infection</i> , 2017, 23, 141-146. | 6.0 | 58 |
| 79 | Systematic reviews of cost-effectiveness in low and middle income countries: a review of reviews. <i>Journal of Development Effectiveness</i> , 2018, 10, 95-120. | 0.8 | 5 |
| 80 | Benefits and Costs of TB Control for the Post-2015 Development Agenda. , 2018, , 255-265. | | 1 |
| 81 | The impact of HIV on the prevalence of asthma in Uganda: a general population survey. <i>Respiratory Research</i> , 2018, 19, 184. | 3.6 | 13 |
| 82 | MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care. <i>PLoS ONE</i> , 2018, 13, e0196003. | 2.5 | 26 |
| 83 | Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon – a qualitative study exploring the experiences and perceptions of patients and healthcare professionals. <i>BMC Health Services Research</i> , 2019, 19, 594. | 2.2 | 8 |
| 84 | Cost of three models of care for drug-resistant tuberculosis patients in Nigeria. <i>BMC Infectious Diseases</i> , 2019, 19, 41. | 2.9 | 12 |
| 85 | What will it take to eliminate drug-resistant tuberculosis?. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 535-546. | 1.2 | 18 |
| 86 | Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. <i>PLoS ONE</i> , 2019, 14, e0217820. | 2.5 | 11 |
| 87 | Implementation of multidrug-resistant tuberculosis (MDR-TB) treatment in Gabon: lessons learnt from the field. <i>Infection</i> , 2019, 47, 811-816. | 4.7 | 6 |
| 88 | Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. <i>European Respiratory Journal</i> , 2019, 53, 1900391. | 6.7 | 81 |
| 89 | Prevalence and associated factors of depression among tuberculosis patients in Eastern Ethiopia. <i>BMC Psychiatry</i> , 2019, 19, 82. | 2.6 | 32 |
| 90 | Strategic investment in tuberculosis control in the Republic of Bulgaria. <i>Epidemiology and Infection</i> , 2019, 147, e304. | 2.1 | 1 |
| 91 | Evaluating the Economic Impact of Plastic and Reconstructive Surgical Efforts in the Developing World: The ReSurge Experience. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 485e-493e. | 1.4 | 10 |
| 92 | A retrospective analysis of treatment outcomes of drug-susceptible TB in Kazakhstan, 2013–2016. <i>Medicine (United States)</i> , 2019, 98, e16071. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 93 | Cost-Effectiveness Analysis of Humanitarian Hand Surgery Trips According to WHO-CHOICE Thresholds. Journal of Hand Surgery, 2019, 44, 93-103. | 1.6 | 19 |
| 94 | Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review. PharmacoEconomics - Open, 2020, 4, 223-233. | 1.8 | 1 |
| 95 | The technological imperative in tuberculosis care and prevention in Vietnam. Global Public Health, 2020, 15, 307-320. | 2.0 | 1 |
| 96 | Impacts of social support on the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis. BMJ Open, 2020, 10, e036985. | 1.9 | 16 |
| 97 | Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia. PLoS ONE, 2020, 15, e0235820. | 2.5 | 7 |
| 100 | The health and economic burden of antimicrobial resistance. , 2020, , 23-44. | | 2 |
| 101 | Tackling antimicrobial resistance in the community. , 2020, , 45-70. | | 2 |
| 102 | The role of vaccines in combating antimicrobial resistance. , 2020, , 181-206. | | 2 |
| 104 | Tackling antimicrobial resistance in the hospital sector. , 2020, , 71-98. | | 0 |
| 105 | Tackling antimicrobial resistance in the food and livestock sector. , 2020, , 99-124. | | 1 |
| 106 | Fostering R&D of novel antibiotics and other technologies to prevent and treat infection. , 2020, , 125-154. | | 0 |
| 107 | Ensuring innovation for diagnostics for bacterial infection to combat antimicrobial resistance. , 2020, , 155-180. | | 0 |
| 108 | “Death is a better option than being treated like this” a prevalence survey and qualitative study of depression among multi-drug resistant tuberculosis in-patients. BMC Public Health, 2020, 20, 848. | 2.9 | 18 |
| 109 | Knowledge and attitudes towards ambulatory treatment of tuberculosis in Kazakhstan. BMC Health Services Research, 2020, 20, 563. | 2.2 | 2 |
| 110 | Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future. Respiration, 2021, 100, 843-852. | 2.6 | 8 |
| 111 | Policy changes and the screening, diagnosis and treatment of drug-resistant tuberculosis patients from 2015 to 2018 in Zhejiang Province, China: a retrospective cohort study. BMJ Open, 2021, 11, e047023. | 1.9 | 3 |
| 112 | Ambulatory Treatment for Multidrug-Resistant Tuberculosis in Rural Haiti: A Mixed-Methods Study of Social and Economic Factors Affecting Timely Diagnosis and Treatment Success. Global Journal of Health Science, 2021, 13, 99. | 0.2 | 1 |
| 113 | Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines. International Journal of Tuberculosis and Lung Disease, 2021, 25, 554-559. | 1.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 114 | The impact of the stratification by degree of clinical severity and abandonment risk of tuberculosis treatment. Jornal Brasileiro De Pneumologia, 2021, 47, e20210018. | 0.7 | 2 |
| 115 | Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO. BMJ Open, 2021, 11, e043954. | 1.9 | 5 |
| 116 | Challenges to Tackling Antimicrobial Resistance. , 2020, , . | | 11 |
| 117 | The role of vaccines in combating antimicrobial resistance. European Journal of Public Health, 2020, 30, . | 0.3 | 2 |
| 119 | Tuberculosis transmission control: a refocused approach. , 0, , 364-380. | | 2 |
| 120 | Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis. PLoS ONE, 2017, 12, e0184270. | 2.5 | 16 |
| 121 | Major Infectious Diseases: Key Messages from Disease Control Priorities, Third Edition. , 2017, , 1-27. | | 28 |
| 123 | Costâ€effectiveness of a comprehensive programme for drug-resistant tuberculosis in China. Bulletin of the World Health Organization, 2015, 93, 775-784. | 3.3 | 12 |
| 124 | Drug resistance TB in India: Challenges, issues and solutions. International Journal of Medical Science and Public Health, 2013, 2, 476. | 0.2 | 0 |
| 125 | Drug Discovery for TB: Frontiers and Perspectives. , 2014, , 3-31. | | 1 |
| 126 | Tackling antimicrobial resistance in the community. European Journal of Public Health, 2020, 30, . | 0.3 | 0 |
| 127 | Cost-Effectiveness and Cost Utility of Treatment of Attention-Deficit/Hyperactivity Disorder: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2021, 31, 578-596. | 1.3 | 7 |
| 128 | The role of civil society in tackling antimicrobial resistance. , 2020, , 207-240. | | 0 |
| 129 | The Progress of Global Antimicrobial Resistance Governance and Its Implication to China: A Review. Antibiotics, 2021, 10, 1356. | 3.7 | 18 |
| 130 | Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis. Lung India, 2015, 32, 402-3. | 0.7 | 0 |
| 131 | Fostering R&D of novel antibiotics and other technologies to prevent and treat infection. European Journal of Public Health, 2020, 30, . | 0.3 | 0 |
| 132 | The health and economic burden of antimicrobial resistance. European Journal of Public Health, 2020, 30, . | 0.3 | 1 |
| 133 | Antibiotic drug resistance TB in India. International Journal of Pharmaceutical Chemistry and Analysis, 2022, 8, 145-151. | 0.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 134 | Budgetary impact of using BPAL for treating extensively drug-resistant tuberculosis. BMJ Global Health, 2022, 7, e007182. | 4.7 | 13 |
| 136 | Cost of TB services in healthcare facilities in Kenya (No 3). International Journal of Tuberculosis and Lung Disease, 2021, 25, 1028-1034. | 1.2 | 10 |
| 137 | Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis. Lung India, 2015, 32, 402. | 0.7 | 2 |
| 139 | TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase IIa trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials, 2022, 23, . | 1.6 | 22 |
| 140 | The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan. PLOS Global Public Health, 2022, 2, e0000567. | 1.6 | 3 |
| 141 | Cost of TB services: approach and summary findings of a multi-country study (Value TB). International Journal of Tuberculosis and Lung Disease, 2022, 26, 1006-1015. | 1.2 | 5 |
| 142 | Impacts of Medical Security Level on Treatment Outcomes of Drug-Resistant Tuberculosis: Evidence from Wuhan City, China. Patient Preference and Adherence, 0, Volume 16, 3341-3355. | 1.8 | 2 |
| 143 | Health technology, quality, law, and ethics. , 2023, , 1037-1095. | | 0 |
| 144 | Economic evaluation of a community health worker model for tuberculosis care in Ho Chi Minh City, Viet Nam: a mixed-methods Social Return on Investment Analysis. BMC Public Health, 2023, 23, . | 2.9 | 1 |
| 145 | Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study. Frontiers in Public Health, 0, 11, . | 2.7 | 3 |
| 146 | Public health benefits of shifting from hospital-focused to ambulatory TB care in Eastern Europe: Optimising TB investments in Belarus, the Republic of Moldova, and Romania. PLOS Global Public Health, 2023, 3, e0001025. | 1.6 | 1 |
| 147 | Psychosocial support interventions to improve treatment outcomes for people living with tuberculosis: a mixed methods systematic review and meta-analysis. EClinicalMedicine, 2023, 61, 102057. | 7.1 | 0 |
| 148 | Cost effectiveness of decentralized care model for managing multi-drug-resistant tuberculosis in low- and middle-income countries: a systematic review protocol. JBI Evidence Synthesis, 0, , . | 1.3 | 0 |
| 149 | Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis. Scientific Reports, 2023, 13, . | 3.3 | 0 |
| 150 | A Generalizable Decision-Making Framework for Selecting Onsite versus Send-out Clinical Laboratory Testing. Medical Decision Making, 2024, 44, 307-319. | 2.4 | 0 |